BiotechTube

Raludotatug Deruxtecan (R-DXd)

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Cancer

Conditions

Gastrointestinal Cancer

Trial Timeline

Apr 1, 2025 → Jan 4, 2029

NCT ID
NCT06864169

About Raludotatug Deruxtecan (R-DXd)

Raludotatug Deruxtecan (R-DXd) is a phase 2 stage product being developed by Daiichi Sankyo for Gastrointestinal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06864169. Target conditions include Gastrointestinal Cancer.

What happened to similar drugs?

8 of 20 similar drugs in Gastrointestinal Cancer were approved

Approved (8) Terminated (3) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Mycophenolate SodiumNovartisApproved
✅myforticNovartisApproved
✅Imatinib MesylateNovartisApproved
✅Imatinib mesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06864169Phase 2Active

Competing Products

20 competing products in Gastrointestinal Cancer

See all competitors
ProductCompanyStageHype Score
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35
EsomeprazoleAstraZenecaPhase 3
40